Literature DB >> 30166721

THE JEREMIAH METZGER LECTURE NOVEL THERAPEUTIC STRATEGIES OF ALLERGIC AND IMMUNOLOGIC DISORDERS.

Ronald G Crystal1, Odelya E Pagovich1.   

Abstract

Advances in understanding the immunological basis and mechanisms underlying allergic and immunologic disorders have led to effective but costly long-term and repetitive biologic therapies. Gene therapy is a rapidly advancing technology, in which a single administration of an adeno-associated virus encoding the therapeutic protein or monoclonal antibody may provide effective long-term therapy for allergic and immunologic disorders. In this review, we summarize the recent studies from our laboratory developing gene therapy strategies to treat hereditary angioedema and peanut allergy. The unraveling of the pathogenesis of immune-based disorders, including hereditary deficiencies of components of the immune system and allergic disorders, has led to the development of therapies using parenteral administration of recombinant proteins or monoclonal antibodies (1). While many of these therapies are highly effective, they are limited by the half-life of the therapeutic protein or antibody, requiring repetitive administration of days to weeks (2-15). The focus of recent work in our laboratory has been to solve this problem by substituting protein/monoclonal antibody administration with gene therapy, where current technology allows for a single administration of the gene coding for a protein or antibody to provide persistent expression of effective levels of the therapeutic protein or antibody. Gene therapy is a drug delivery platform which uses genetic material, usually in the form of coding exons of the therapeutic gene, to correct, compensate for, or prevent the development of an abnormal phenotype (16). Originally conceptualized as a strategy to treat rare hereditary disorders, gene therapy is being developed for a wide range of human disorders, including common acquired conditions (17-20). In this review, we will describe how we have adopted gene therapy technology to develop therapies for immune-related disorders, using as examples hereditary angioedema, an inherited autosomal dominant disorder, and peanut allergy, a common acquired allergic disorder.

Entities:  

Mesh:

Year:  2018        PMID: 30166721      PMCID: PMC6116601     

Source DB:  PubMed          Journal:  Trans Am Clin Climatol Assoc        ISSN: 0065-7778


  95 in total

1.  AAV-directed persistent expression of a gene encoding anti-nicotine antibody for smoking cessation.

Authors:  Martin J Hicks; Jonathan B Rosenberg; Bishnu P De; Odelya E Pagovich; Colin N Young; Jian-ping Qiu; Stephen M Kaminsky; Neil R Hackett; Stefan Worgall; Kim D Janda; Robin L Davisson; Ronald G Crystal
Journal:  Sci Transl Med       Date:  2012-06-27       Impact factor: 17.956

2.  House dust mite-induced airway changes in hu-SCID mice.

Authors:  C Duez; J Kips; J Pestel; K Tournoy; A B Tonnel; R Pauwels
Journal:  Am J Respir Crit Care Med       Date:  2000-01       Impact factor: 21.405

3.  NOD/SCID/gamma(c)(null) mouse: an excellent recipient mouse model for engraftment of human cells.

Authors:  Mamoru Ito; Hidefumi Hiramatsu; Kimio Kobayashi; Kazutomo Suzue; Mariko Kawahata; Kyoji Hioki; Yoshito Ueyama; Yoshio Koyanagi; Kazuo Sugamura; Kohichiro Tsuji; Toshio Heike; Tatsutoshi Nakahata
Journal:  Blood       Date:  2002-11-01       Impact factor: 22.113

4.  Enhanced survival of the LINCL mouse following CLN2 gene transfer using the rh.10 rhesus macaque-derived adeno-associated virus vector.

Authors:  Dolan Sondhi; Neil R Hackett; Daniel A Peterson; Jamie Stratton; Michael Baad; Kelly M Travis; James M Wilson; Ronald G Crystal
Journal:  Mol Ther       Date:  2006-12-19       Impact factor: 11.454

5.  Retroviral vector-mediated high-efficiency expression of adenosine deaminase (ADA) in hematopoietic long-term cultures of ADA-deficient marrow cells.

Authors:  C Bordignon; S F Yu; C A Smith; P Hantzopoulos; G E Ungers; C A Keever; R J O'Reilly; E Gilboa
Journal:  Proc Natl Acad Sci U S A       Date:  1989-09       Impact factor: 11.205

Review 6.  Adeno-associated viral vectors for the treatment of hemophilia.

Authors:  Katherine A High; Xavier M Anguela
Journal:  Hum Mol Genet       Date:  2015-11-27       Impact factor: 6.150

7.  Human IgE in SCID mice reconstituted with peripheral blood mononuclear cells from Dermatophagoides pteronyssinus-sensitive patients.

Authors:  J Pestel; P Jeannin; Y Delneste; J P Dessaint; J Y Cesbron; A Capron; A Tsicopoulos; A B Tonnel
Journal:  J Immunol       Date:  1994-10-15       Impact factor: 5.422

8.  In Utero Transfer of Adeno-Associated Viral Vectors Produces Long-Term Factor IX Levels in a Cynomolgus Macaque Model.

Authors:  Citra N Z Mattar; Irene Gil-Farina; Cecilia Rosales; Nuryanti Johana; Yvonne Yi Wan Tan; Jenny McIntosh; Christine Kaeppel; Simon N Waddington; Arijit Biswas; Mahesh Choolani; Manfred Schmidt; Amit C Nathwani; Jerry K Y Chan
Journal:  Mol Ther       Date:  2017-04-24       Impact factor: 11.454

9.  Advances in Non-Viral DNA Vectors for Gene Therapy.

Authors:  Cinnamon L Hardee; Lirio Milenka Arévalo-Soliz; Benjamin D Hornstein; Lynn Zechiedrich
Journal:  Genes (Basel)       Date:  2017-02-10       Impact factor: 4.096

10.  Bradykinin and the pathogenesis of hereditary angioedema.

Authors:  Allen P Kaplan
Journal:  World Allergy Organ J       Date:  2011-04       Impact factor: 4.084

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.